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Abstract
Background: Intestinal schistosomiasis is one of the neglected tropical parasitic diseases caused by Schistosoma
mansoni. Currently, the control measures for the disease are mainly based on mass drug administration (MDA) with
praziquantel (PZQ) targeting the school-age children. In Ethiopia, the potential foci for schistosomiasis and therapeutic
efficacy of PZQ among school-age children remain poorly explored. Therefore, we determined both the prevalence
and intensity of S. mansoni infection and the therapeutic efficacy of PZQ among school children in the Manna District
(new foci for S. mansoni), Jimma Zone, southwest Ethiopia.
Methods: A cross-sectional study was conducted among the school children aged between 6 and 18 years in three
primary schools in Manna district from March to April 2014. For diagnosis of S. mansoni, a single stool sample was
obtained from each child and processed using single Kato Katz and examined under light microscopy. A questionnaire
was used to collect demographic information of the school children participated in the study. School children
excreting eggs of S. mansoni were administered with 40 mg/kg of PZQ and re-examined after three weeks
post-treatment. The therapeutic efficacy of PZQ against S. mansoni was evaluated by means of cure rate and
egg reduction rate.
Results: The overall prevalence of S. mansoni among the school children in the three primary schools in Manna District
was 24.0 %. Higher prevalence was recorded for males 25.6 % (61/238) than for females 22.5 % (59/262). Majority (27.5 %)
of infection intensity was light with mean faecal egg count (FEC) of 202 eggs per gram (EPG). The therapeutic efficacy of
PZQ at a dose of 40 mg/kg was highly efficient (cure rate of 99.1 % and egg reduction rate of 99.9 %) among the school
children in the three primary schools in Manna District.
Conclusions: The school children in the three primary schools of Manna District, Jimma Zone were at moderate risk of
the morbidity caused by S. mansoni (prevalence > 10 % and < 50 % according to WHO threshold), and hence a biannual
MDA with PZQ is required. PZQ available on the local market was found efficient and can be recommended for
individual treatment in absence of MDA. The therapeutic efficacy of PZQ at 40 mg/kg against S. mansoni was
high in the study area.
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Background
Intestinal schistosomiasis is a chronic parasitic disease
caused by the trematode Schistosoma mansoni [1]. It is
one of the neglected tropical parasitic diseases (NTDs)
that causes severe morbidity and mortality among sus-
ceptible segments of the population. Its importance in
terms of socioeconomic and public health in tropical
and subtropical countries is high. In tropical developing
countries about 779 million people were estimated to
be at risk of infection (85 % in Africa), 207 million
people are infected (> 97 % in Africa) and 120 million
people diseased (20 millions severely) [2, 3]. The annual
mortality is estimated to be 15,000–280,000 and 1.7–
4.5 million disability adjusted life years are lost due to
disease [4].
In Africa, 31 countries including Ethiopia share the great
burden of schistosomiasis and millions of people have
been suffering from the disease. The burden of schisto-
somiasis due to S. mansoni is 28.8 million in Nigeria, 19
million Tanzania, 15.2 million Ghana, 14.9 million Congo
and 13.2 million Mozambique [3, 5]. In Ethiopia, the en-
demicity of intestinal schistosomiasis has long been estab-
lished and estimates made in the early 1980s documented
the number of people at risk of infection as 18 millions
[6]. Several epidemiological studies indicate that intestinal
schistosomiasis due to S. mansoni infection is widely dis-
tributed in different parts of Ethiopia with prevalences as
high as 90 % in school-age children [7].
Children in the developing countries live in areas with
poor sanitation and most often spend time swimming or
bathing in the water bodies contaminated with cercariae,
the infective stages of schistosomes [8]. The hygiene and
playing behavior in water bodies increases the risk of be-
ing infected by S. mansoni [9].
In the past, the preventive measures of schistosomiaiss
largely focused on decreasing or interrupting transmis-
sion of the infection; however such measures have not
been continued due to high operation cost/difficult im-
plementation logistics [5]. The advent of inexpensive, ef-
ficacious and safe drugs has made chemotherapy the
most cost-effective strategy thereby shifting control em-
phasis to disease control [10].
Oxamniquine, metrifonate and PZQ are the main
drugs that have been used widely for control of schisto-
somiasis [11, 12]. Among these anti-schistosomial drugs,
PZQ is a broad spectrum drug that is effective against
all species of Schistosoma. It is administered orally at a
standard single dose of 40 mg/kg body weight and well
tolerated. The side effects of the drug are mild and tran-
sient, and mostly related to the gastrointestinal tract ef-
fects, such as abdominal pain, nausea, vomiting,
anorexia and diarrhea [13].
The efficacy of the drug is considered as sufficient
when the cure rate (CR) is 60–90 % and egg reduction
rate (ERR) is > 90 %, while facilitating patients’ compli-
ance especially among children [14, 15]. Most of the
time population treatment with PZQ produces CR of
over 70 %. However, efficacy of treatment is influenced
by a number of factors, such as the epidemiological situ-
ations and expands on the prevailing ecological condi-
tions which may affect PZQ efficacy [16]. Efficacy of
PZQ decreases with pre-treatment intensity of infection,
number of pre-patent infections, diagnostic sensitivity
and age of the treated individuals [17]. Moreover, poor
drug quality and poor patient compliance may also nega-
tively impact the effectiveness of the treatment, and even
optimal timing at which treatment is evaluated also af-
fects the outcome of the treatment [18].
Some studies conducted on the efficacy of PZQ against
S. mansoni tested in Senegal reported CR as low as 18 %
raising the fear about the effectiveness of the drug [17].
However, there have been reports of S. mansoni resist-
ance to PZQ from studies carried out in Egypt with fail-
ure to CR of 1.6 % of those infected with S. mansoni in a
Nile Delta village [19] and Kenya [20]. There are reports
of low CR of 73.6 % and ERR of 68.2 % of PZQ in south-
ern part of Ethiopia [21].
Our study area is not yet included in the epidemio-
logical map of S. mansoni in Ethiopia and there are vari-
ous reports providing evidence for parasite occurrence
from the local health offices in the district. To the best
of our knowledge, the epidemiology of S. mansoni and
the therapeutic efficacy of PZQ have not been evaluated
in the study area. Therefore, we determined the preva-
lence and intensity of S. mansoni infections and evalu-
ated the therapeutic efficacy of PZQ against S. mansoni




The study was conducted between March and April,
2014 among students of three primary schools namely
Kore konjo, Wollo sefar and Saye odo in Mana District,
Jimma Zone, Oromia Regional State, southwest,
Ethiopia. The district is located 382 km away from the
capital city of the country and 32 km away from Jimma
Town in Jimma Zone. The district is located at an aver-
age altitude of about 1450 m above sea level. It is gener-
ally characterized by warm climate with a mean annual
maximum temperature of 25 °C and a mean annual
minimum temperature of 18 °C. The annual rainfall
ranges from 1138 to 1690 mm (Report document 2013/
2014 of Jimma Zone administration). There are different
water sources in the district which the population fre-
quently used for domestic purposes and thus could be
potential risk factor for infection with S. mansoni.
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Study population
Study populations were all school children enrolled in
three primary schools of Manna district during study
period. In each school, we stratified students according
to three age groups (age 6–9 years, age 10–14 years and
age 15–18 years). Five hundred students were screened
to include at least 100 S. mansoni-infected children at
baseline screen based on WHO guideline and other lit-
erature for assessing the efficacy of anti-helminthic
drugs against schistosomiasis and soil-transmitted
helminthiases [15, 22].
Sampling, study design and sample processing
Simple random sampling technique was used to select the
study participants based on their name list from their
grades. School-based cross-sectional study was employed
among school children of three primary schools in the
Manna District. Stool samples were collected using dry,
clean, labelled plastic containers. Kato-Katz thick smear
was prepared from each stool sample for the detection
and quantification of the eggs of S. mansoni and other
soil-transmitted helminths (STH). The quantity of S. man-
soni eggs was determined before and after treatments to
determine the intensity of infection. Before the adminis-
tration of PZQ, all S. mansoni-infected students were pro-
vided biscuits and a cup of tea. Students who were treated
with PZQ were followed by senior health officer and nurse
for four hours and those who vomited within two hours
after oral administration of the drug were excluded from
the analysis.
Praziquantel efficacy
In post-treatment, a Kato-Katz thick smear was proc-
essed for each specimen to determine CR and ERR.
Thus, efficacy of 40 mg/kg PZQ against S. mansoni was
determined exactly on day 21 post-treatment and its effi-
cacy were assessed as ERR (%) as follows [15]:
ERR %ð Þ ¼ 100
 1−Arithmetic mean of egg counts at follow‐up
Arithmetic mean of egg counts at base line
 
The indicator of choice for drug efficacy is ERR. PZQ
efficacy is satisfactory when ERR ≥ 90 % with the refer-
ence value ≥ 90 %; doubtful when ERR is lower than the
reference value by less than 10 %; and reduced if ERR is
inferior by value of at least 10 % points than the refer-
ence value [15].
Data processing and analysis
Data were coded, entered and cleaned by using EPIIFO.
Data processing and analysis were carried out using
SPSS version 20.0. CR was calculated as the ratio of the
number of study participants who were negative after
treatment to the number of study participants who were
positive before treatment and who completed the study
and ERR was calculated based on arithmetic means as
described above. Infection intensity of S. mansoni was
provided as geometric mean.
Data quality assurance
Refreshment training was given to data collectors and la-
boratory technicians about Kato-Katz smears by experi-
enced personnel in the field. During data processing, the
quality of data was assured by coding and double entry.
From both positive and negative Kato-Katz smears, 10 %
were randomly selected and re-read by two independent
medical laboratory experts who were blinded to the pri-
mary result. Moreover, fresh working solution of
malachite-green was used routinely to maintain the
quality of the smear.
Results
Socio-demographic characteristics of study participants
A total of 500 students (238 males and 262 females)
were involved from three primary schools selected in
Manna District. The largest number of study partici-
pants, 379 (75.8 %) was from the age group 10–14 years.
Prevalence and intensity of S. mansoni infection
The overall prevalence of S. mansoni among students
was 24 % (120/500). The prevalence was 25.6 % (61/238)
and 22.5 % (59/262) for the male and female students,
respectively. The prevalence ranged from 7.6 to 41.4 %
among the schools with the highest prevalence 41.4 %
(41/99) in Kore Konjo School (Table 1). Majority of the
infection intensity was classified as low with maximum
EPG of 1848 (Fig. 1).
Table 1 Socio-demographic characteristics and prevalence of S.
mansoni among school children in three primary schools of
Manna District, Jimma Zone, southwest Ethiopia, 2014
Variables S. mansoni infection status Total (%)
No. of positive (%) No. of negative (%)
Sex
Male 61 (25.6) 177 (74.4) 238 (47.6)
Female 59 (22.5) 203 (77.5) 262 (52.4)
Age (years)
6–9 8 (10.4) 69 (89.6) 77 (15.4)
10–14 98 (26.1) 278 (73.9) 376 (75.2)
15–18 14 (29.8) 33 (70.2) 47 (9.4)
Schools
Kore Konjo 41 (41.4) 58 (58.6) 99 (19.8)
Saye Odo 66 (28.6) 165 (71.4) 231 (46.2)
Wollo Sefar 13 (7.6) 157 (92.4) 170 (34)
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The therapeutic efficacy of praziquantel
Among the study participants, 120 students were infected
with S. mansoni and treated with 40 mg/kg PZQ at base-
line screening. Of the 120 infected students, five were ex-
cluded from the analysis of PZQ efficacy after treatment
with 40 mg/kg PZQ. Two of them vomited immediately
after 20 min of drug administration and three refused to
provide stool on the day of post-examination. The CR of
PZQ against S. mansoni infected school children was
99.1 %. The ERR of 40 mg/kg PZQ was found to be
99.9 %. ERR and CR had no statistically significant associ-
ation with age of the school children and intensity S. man-
soni infection (χ2 = 1.74, P = 0.424) (Table 2).
Discussion
In the present study, the overall infection with S. mansoni
among students of three primary schools in Manna District
was 24 %. The therapeutic efficacy of PZQ at 40 mg/kg
body weight against S. mansoni infection in the study area
had 99.9 % ERR and 99.1 % CR. Majorities of infection in-
tensities and the mean intensity of infection were low.
The prevalence rate in the present study was higher than
those reported from Brazil (14.4 %), Nigeria (4.6 % and
12.6 %) and Ghana (19.8 %) [23–26]. Similarly, our find-
ings were higher than two previous investigations con-
ducted in Ethiopia including Tigray (5.95 %) and Jimma
(2.1 %) [27, 28]. The difference could be due to the study
period and the method of laboratory diagnosis employed.
However, there are reports with higher prevalence from
northwestern Tanzania (64.3 %) [29], and from southern
Tigray (73.9 %), Gonder (89.9 %), Wondo Genet (74.9 %)
and Wollega (67.6 %) from Ethiopia [7, 21, 30–32]. The
difference might be due to long time endemicity of the
parasite in these study areas than the current emerging
foci of our study area, the study design employed and
ecological differences.
There is almost comparable report from Uganda
(27.8 %) [33] and other similar studies from Ethiopia in-
cluding Mekelle (23.9 %) [34] and southeast of Lake
Langano (21.2 %) [35].
The infection intensity in our study indicated low in-
fection levels comparable with findings from Timuga
and Waja from Tigray [36] and Mekelle City [34].
However, moderate infection intensities were reported
from Wondo Genet [21] and Wollega [32] in Ethiopia.
The difference may be explained by the frequency of
students’ contact with contaminated water-bodies and
the burden of the adult worms hosted.
In the current study area, PZQ at 40 mg/kg had
higher efficacy when compared with the reports from
Senegal (CR = 42.5 % and ERR = 70.7 %) [37] and
Nigeria (CR = 49.4 % and ERR = 57.1 %) [14]. This
difference could be due to baseline infection inten-
sity, duration of post-treatment, presence of imma-
ture stages of the parasite. Moreover, the new
emergence of S. mansoni in the study area and the
lack of previous exposure of school children to PZQ
treatment as mass drug administration may contrib-
ute to the high efficacy. Previous efficacy study car-
ried out at four weeks of post-treatment in northeast
Ethiopia have reported lower CR (83.2 %) [38].
Moreover, lower CR (73.6 %) and ERR (68.2 %) were
reported from other studies undertaken in Wondo
Genet, Ethiopia [21]. The difference might be due to
the intensity of infection, brand of PZQ used, geo-
graphical variation, and the presence of immature
stages of the parasite. On the contrary, the efficacy
of PZQ at 40 mg/kg in the present study was higher
compared to the study reported from Senegal (CR
18–38 %) [39], Niger (ERR 55.2–60.2 %) [40]
eventhough the duration of post-treatment was simi-
lar to that of our study (three weeks). The variation
of PZQ efficacy might be due to the infection inten-
sity and geographical location.
The efficacy of PZQ at 40 mg/kg (CR = 99.1 % and
ERR = 99.9 %) in the present study is almost comparable
to the reports from South Africa (CR = 100 %) [41],
Sudan (CR 89–92.1 % and ERR 96.4–99.4 %) [42], Egypt
(CR 73.3–92.8 %) [19] and Kenya (ERR = 92.6 % [43].
Moreover, there are two reports from Ethiopia including
Tigray, Timuga and Waja (CR of 93.44 and 88.9 %) [36],
Wollega (CR of 80.9 % and ERR of 99.5 %) [32],
Fig. 1 Infection intensity of S. mansoni among school children in
Manna District, Jimma Zone, southwest Ethiopia, 2014
Table 2 Cure rate of PZQ against S. mansoni-infected school
children in Manna District, Jimma Zone, southwest Ethiopia,
2014





6–9 years 6 (85.7) 1 (14.3) 7 (6.1) 1.71 0.424
10–14 years 94 (100) 0 94 (81.7)
15–19 years 14 (100) 0 14 (12.2)
Total 114 (99.1) 1 (0.9) 115 (100)
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respectively, from Ethiopia at different post-treatment
durations with comparable efficacy. Furthermore, the
efficacy of PZQ at 40 mg/kg among students in
present study is comparable with the findings from Senegal
(CR = 93 % and ERR = 90 %) [18], Cameroon (CR = 95.3 %)
[22], and Ethiopia (CR = 94 % and ERR = 97 % [44] with the
same post-treatment duration.
Conclusions
The students in the three primary schools of Manna
District, Jimma Zone were at moderate risk of the
morbidity caused by S. mansoni (prevalence > 10 % and
< 50 % according to WHO threshold), and hence a bian-
nual MDA with PZQ is required. PZQ available on the
local market revealed efficiency and can be recom-
mended for individual treatment in absence of MDA.
The infection intensity of S. mansoni among the school
children in the current study was light. Among school
children, the age group 10–14 years is the most affected.
PZQ at 40 mg/kg has 99.9 % ERR and 99.1 % CR. There-
fore, the therapeutic efficacy of PZQ at 40 mg/kg against
S. mansoni was high in the study area.
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